Actavis May Go Public Within Three Years

Actavis is well placed to benefit from the increasing uptake of generic drugs in Western and Eastern Europe as demonstrated by our favourable growth projections for generic pharmaceuticals. If Actavis can lower its net debt and increase profitability, CFW believes it offers an attractive investment opportunity.

To read the full article, please choose one of the following options: